Prognostic impact over time of ischaemic heart disease vs. non-ischaemic heart disease in heart failure

Heart Failure

Is Time of the Essence? The Impact of Time of Hospital Presentation in Acute Heart Failure: Insights From ASCEND-HF Trial

JACC Heart Fail.

Cerbin LP, Ambrosy AP, Greene SJ, Armstrong PW, Butler J, Coles A, DeVore AD, Ezekowitz JA, Hernandez AF, Metra M, Starling RC, Tang W, Teerlink JR, Voors AA, Wu A, O'Connor CM, Mentz RJ

doi: 10.1016/j.jchf.2018.01.018.

Atrial FibrillationHeart Failure

Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and heart failure

ESC Heart Fail.

Martinez BK, Bunz TJ, Eriksson D, Meinecke AK, Sood NA, Coleman CI

doi: 10.1002/ehf2.12365.

Heart, Artery and Coronary DiseasesHeart FailureThrombosis and Stroke

A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial

Eur Heart J.

Mehra MR, Vaduganathan M, Fu M, Ferreira JP, Anker SD, Cleland JGF, Lam CSP, van Veldhuisen DJ, Byra WM, Spiro TE, Deng H, Zannad F, Greenberg B

doi: 10.1093/eurheartj/ehz427.

Heart Failure

Non-invasive telemedical care in heart failure patients and stroke: post hoc analysis of TIM-HF and TIM-HF2 trials

ESC Heart Fail.

Tütüncü S, Honold M, Koehler K, Deckwart O, Koehler F, Haeusler KG

doi: 10.1002/ehf2.12679.

Heart Failure

The impact of COVID-19 on heart failure hospitalization and management: report from a Heart Failure Unit in London during the peak of the pandemic

Eur J Heart Fail.

Bromage DI, Cannata A, Rind IA, Gregorio C, Piper S, Shah AM, McDonagh TA

doi: 10.1002/ejhf.1925.

Heart Failure

The role of ventricular-arterial coupling in cardiac disease and heart failure: assessment, clinical implications and therapeutic interventions. A consensus document of the European Society of Cardiology Working Group on Aorta & Peripheral Vascular Diseases, European Association of Cardiovascular Imaging, and Heart Failure Association

Eur J Heart Fail.

Ikonomidis I, Aboyans V, Blacher J, Brodmann M, Brutsaert DL, Chirinos JA, De Carlo M, Delgado V, Lancellotti P, Lekakis J, Mohty D, Nihoyannopoulos P, Parissis J, Rizzoni D, Ruschitzka F, Seferovic P, Stabile E, Tousoulis D, Vinereanu D, Vlachopoulos C, Vlastos D, Xaplanteris P, Zimlichman R, Metra M

doi: 10.1002/ejhf.

Heart Failure

Is heart failure misdiagnosed in hospitalized patients with preserved ejection fraction? From the European Society of Cardiology - Heart Failure Association EURObservational Research Programme Heart Failure Long-Term Registry

ESC Heart Fail.

Kapłon-Cieślicka A, Laroche C, Crespo-Leiro MG, Coats AJS, Anker SD, Filippatos G, Maggioni AP, Hage C, Lara-Padrón A, Fucili A, Drożdż J, Seferovic P, Rosano GMC, Mebazaa A, McDonagh T, Lainscak M, Ruschitzka F, Lund LH, Heart Failure Association (HFA) of the European Society of Cardiology (ESC) and the ESC Heart Failure Long-Term Registry Investigators

doi: 10.1002/ehf2.12817.

Heart Failure

Prognostic Models Derived in PARADIGM-HF and Validated in ATMOSPHERE and the Swedish Heart Failure Registry to Predict Mortality and Morbidity in Chronic Heart Failure

JAMA Cardiol.

Simpson J, Jhund PS, Lund LH, Padmanabhan S, Claggett BL, Shen L, Petrie MC, Abraham WT, Desai AS, Dickstein K, Køber L, Packer M, Rouleau JL, Mueller-Velten G, Solomon SD, Swedberg K, Zile MR, McMurray JJV

doi: 10.1001/jamacardio.2019.5850.

Heart, Artery and Coronary DiseasesHeart Failure

Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF)

Eur J Heart Fail.

Rickenbacher P, Kaufmann BA, Maeder MT, Bernheim A, Goetschalckx K, Pfister O, Pfisterer M, Brunner-La Rocca HP; TIME-CHF Investigators

doi: 10.1002/ejhf.798.

Related content

Is Time of the Essence? The Impact of Time of Hospital Presentation in Acute Heart Failure: Insights From ASCEND-HF Trial

Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and heart failure

A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial

Non-invasive telemedical care in heart failure patients and stroke: post hoc analysis of TIM-HF and TIM-HF2 trials

The impact of COVID-19 on heart failure hospitalization and management: report from a Heart Failure Unit in London during the peak of the pandemic

Is heart failure misdiagnosed in hospitalized patients with preserved ejection fraction? From the European Society of Cardiology - Heart Failure Association EURObservational Research Programme Heart Failure Long-Term Registry

Prognostic Models Derived in PARADIGM-HF and Validated in ATMOSPHERE and the Swedish Heart Failure Registry to Predict Mortality and Morbidity in Chronic Heart Failure

Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF)